Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
NCT ID: NCT00652899
Last Updated: 2017-12-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
14 participants
INTERVENTIONAL
2008-03-31
2009-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This phase II trial is studying how well giving laboratory-treated donor natural killer cells together with aldesleukin works when given after cyclophosphamide, fludarabine, and total-body irradiation in treating patients with recurrent and/or metastatic ovarian, fallopian tube, or primary peritoneal cancer.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* To evaluate the in vivo expansion of an infused allogeneic natural killer (NK) cell product following a preparative regimen comprising cyclophosphamide, fludarabine phosphate, and total-body irradiation in treating patients with recurrent and/or metastatic ovarian, fallopian tube, or primary peritoneal cancer.
Secondary
* To characterize the quantitative and qualitative toxicities of this treatment regimen.
* To estimate disease response (complete or partial response) or clinical benefit (stable disease for \> 6 months) as measured by Response Evaluation Criteria in Solid Tumours (RECIST) criteria.
* To estimate time to progression and overall survival.
* To estimate the association between clinical response and donor/recipient KIR ligand matching status.
Tertiary
* To evaluate immune activation of the in vivo expanded haploidentical allogeneic NK cells and its effect on the immune system.
OUTLINE:
* Preparative regimen: Patients receive fludarabine phosphate IV on days 6 to 2 preceding natural killer (NK) cell infusion and cyclophosphamide IV on days 5 and 4 preceding NK cell infusion. Patients also undergo total-body irradiation on day 1 preceding NK cell infusion.
* Allogeneic natural killer (NK) cell administration and aldesleukin: Patients receive aldesleukin-activated haploidentical allogeneic NK cells intravenously (IV) on day 0. Beginning 4-6 hours after allogeneic NK cell infusion, patients receive aldesleukin subcutaneously (SC) 3 times a week for 6 doses.
Patients achieving any initial response (complete or partial response) or a clinical benefit (stable disease for \> 6 months) who progress after 6 months may receive 1 re-treatment course as above.
Blood samples are collected at baseline, on days 0, 7, 14, and 28, and then at 2 and 3 months post NK cell infusion for cytokine measurements, immunophenotyping, functional analyses, and testing for persistence of donor cells.
After completion of study treatment, patients are followed periodically for at least 1 year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Total Body Irradiation
This group includes patients that received all chemotherapy, infusion of natural killer (NK) cells and total body irradiation per protocol.
1\. Allopurinol 300 mg by mouth daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post NK cell infusion. 2. Cyclophosphamide 60 mg/m\^2 on Days 4 and 5 preceding NK cell infusion. 3. Fludarabine phosphate 25 mg/m\^2 on Days 6 through 2 preceding NK cell infusion. 4. Radiation: total-body irradiation 200 cGy Day 1 preceding NK cell infusion. 5. Allogeneic natural killer cells- Given day 0 - dose of 1.5-8.0 \* 10\^7/kg. 6. Aldesleukin 10 million units 3 times/week for a total of 6 doses beginning Day 0.
Allopurinol
All patients are to receive allopurinol 300 mg PO daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post natural killer cell infusion.
Cyclophosphamide
60 mg/m\^2 on Days 4 and 5 preceding natural killer cell infusion.
Fludarabine phosphate
25 mg/m\^2 on Days 6 through 2 preceding natural killer cell infusion.
total-body irradiation
200 cGy Day 1 preceding natural killer cell infusion.
Allogeneic natural killer cells
Given day 0 - dose of 1.5-8.0 \* 10\^7/kg
Aldesleukin
10 MU 3 times/week for a total of 6 doses beginning Day 0
No Total Body Irradiation
This group includes patients that received chemotherapy and infusion of natural killer cells, but did not receive total body irradiation.
1\. Allopurinol 300 mg by mouth daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post NK cell infusion. 2. Cyclophosphamide 60 mg/m\^2 on Days 4 and 5 preceding NK cell infusion. 3. Fludarabine phosphate 25 mg/m\^2 on Days 6 through 2 preceding NK cell infusion. 4. Allogeneic natural killer cells- Given day 0 - dose of 1.5-8.0 \* 10\^7/kg. 5. Aldesleukin 10 million units 3 times/week for a total of 6 doses beginning Day 0.
Allopurinol
All patients are to receive allopurinol 300 mg PO daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post natural killer cell infusion.
Cyclophosphamide
60 mg/m\^2 on Days 4 and 5 preceding natural killer cell infusion.
Fludarabine phosphate
25 mg/m\^2 on Days 6 through 2 preceding natural killer cell infusion.
Allogeneic natural killer cells
Given day 0 - dose of 1.5-8.0 \* 10\^7/kg
Aldesleukin
10 MU 3 times/week for a total of 6 doses beginning Day 0
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Allopurinol
All patients are to receive allopurinol 300 mg PO daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post natural killer cell infusion.
Cyclophosphamide
60 mg/m\^2 on Days 4 and 5 preceding natural killer cell infusion.
Fludarabine phosphate
25 mg/m\^2 on Days 6 through 2 preceding natural killer cell infusion.
total-body irradiation
200 cGy Day 1 preceding natural killer cell infusion.
Allogeneic natural killer cells
Given day 0 - dose of 1.5-8.0 \* 10\^7/kg
Aldesleukin
10 MU 3 times/week for a total of 6 doses beginning Day 0
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Measurable disease (≥ 1 cm) per Response Evaluation Criteria for Solid Tumors (RECIST) - patients with bone as their only site of metastatic disease will not be eligible
* Progression on or failure to respond to at least 2 salvage chemotherapy regimens (2 regimens given for disease recurrence) for recurrent/metastatic ovarian, fallopian tube, or primary peritoneal cancer
* If history of brain metastases, stable for at least 3 months after treatment - A brain computed tomography (CT) scan will only be required in subjects with known brain metastases at the time of enrollment or in subjects with new clinical signs or symptoms suggestive of brain metastases.
* Available related HLA-haploidentical natural killer (NK) cell donor (by at least class I serologic typing). If biologic parents or siblings are available, can proceed with work-up of subject prior to return of human leukocyte antigen (HLA) typing results.
* Age 18 years or older
* Gynecology Oncology Group (GOG) performance status 0 or 1
* Adequate organ function as determined by the following criteria within 14 days of study enrollment:
* Bone marrow: platelets ≥ 80,000 x 10\^9/L and hemoglobin ≥ 9g/dL, unsupported by transfusions; absolute neutrophil count (ANC) ≥ 1000 x 10\^9/L, unsupported by granulocyte-colony stimulating factor (G-CSF) or granulocyte macrophage-colony stimulating factor (GM-CSF)
* Renal function: creatinine (Cr) ≤ 2.0 mg/dL
* Liver function: aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, alkaline phosphatase \< 5 times upper limit of institutional normal
* Cardiac: Left ventricular ejection fraction \>40%
* Pulmonary function: \> 50% corrected Carbon Monoxide Diffusing Capacity (DLCO) and Forced expiratory volume in one second (FEV1), if presence of pleural effusion due to metastatic disease \>40% corrected DLCO and FEV1 acceptable.
* Able to be off prednisone or other immunosuppressive medications for at least 3 days prior to Day 0
* Voluntary written informed consent signed before performance of any study related procedure not part of normal medical care.
Exclusion Criteria
* Active infection - subjects must be afebrile, off antibiotics, and with no uninvestigated radiologic lesions (infiltrates or lesions with negative cultures or biopsies are allowed).
Human anti-mouse antibody (HAMA) monitoring: All subjects will be questioned about prior exposure to antibody therapy (including OKT3, Rituximab, Trastuzumab, etc). Responses will be recorded and reported to the FDA as part of the annual report. For subjects with no prior antibody therapy exposure, no further action will be taken. For subjects who have received previous antibody therapies 10 ml of serum (red top tube) will be drawn before starting therapy and banked per section 8.1. The presence of HAMA will not exclude a patient from the study.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Masonic Cancer Center, University of Minnesota
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Melissa A. Geller, MD
Role: PRINCIPAL_INVESTIGATOR
Masonic Cancer Center, University of Minnesota
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UMN-MT2007-19R
Identifier Type: OTHER
Identifier Source: secondary_id
UMN-WCC-53
Identifier Type: OTHER
Identifier Source: secondary_id
UMN-0712M23462
Identifier Type: OTHER
Identifier Source: secondary_id
2007LS138
Identifier Type: -
Identifier Source: org_study_id